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Middle East and North Africa
Background: HIV prevalence is low in the Middle East and North Africa (MENA) region, though the risk or
potential for further spread in the future is not well understood. Behavioral surveys are limited in this region
and when available have serious limitations in assessing the risk of HIV acquisition. We demonstrate the
potential use of herpes simplex virus-2 (HSV-2) seroprevalence as a marker for HIV risk within MENA.
Methods:Wedesigned amathematicalmodel to assesswhetherHSV-2 prevalence can be predictive of future
HIV spread. We also conducted a systematic literature review of HSV-2 seroprevalence studies within MENA.
Results:We found that HSV-2 prevalence data are rather limited in this region. Prevalence is typically
low among the general population but high in established core groups prone to sexually transmitted
infections such as men who have sex with men and female sex workers. Our model predicts that if HSV-2
prevalence is low and stable, then the risk of future HIV epidemics is low. However, expanding or high HSV-
2 prevalence (greater than about 20%), implies a risk for a considerable HIV epidemic. Based on available
HSV-2 prevalence data, it is not likely that the general population in MENA is experiencing or will
experience such a considerable HIV epidemic. Nevertheless, the risk for concentrated HIV epidemics among
several high-risk core groups is present.
Conclusions: HSV-2 prevalence surveys provide a useful mechanism for identifying and corroborating
populations at risk for HIV within MENA. HSV-2 serology offers an effective tool for probing hidden sexual
risk behaviors in a region where quality behavioral data are limited.
© 2010 Elsevier B.V. All rights reserved.Introduction
The Middle East and North Africa (MENA) region is perceived as “a
real hole in terms of HIV/AIDS epidemiological data” (Mark Kline)
(Bohannon, 2005). Despite emerging data revealing low HIV
prevalence, surveys suggest pockets of high risk (Abu-Raddad et al.,
2010a,b; Egypt Ministry of Health and Population National AIDS
Program, 2006; Elrashied, 2006; Jahani et al., 2009; Khattabi and
Alami, 2005; Kriitmaa et al., 2010; Mahfoud et al., 2010; Marcelin
et al., 2002; Pakistan National AIDS Control Program, 2008). There is age — Qatar, Qatar Foundation,
4492 8222.
Abu-Raddad).
l rights reserved.notion that risky sexual practices do occur in MENA but these
practices are hidden due to the conservative nature of MENA societies
(Kelley and Eberstadt, 2005).
Though there has been an increase in the number of studies
assessing sexual risk behavior among populations withinMENA (Abu-
Raddad et al., 2010a,b), the representation, quality, and reproducibility
of these data are open to question. Sexualmeasures inMENA tend to be
limited due to minimal surveillance efforts, methodological limita-
tions, conservative nature of MENA societies, and stigma and illegality
associated with some forms of sexual practices (Abu-Raddad et al.,
2010a). Several integrated bio-behavioral surveillance surveys were
recently conducted in MENA among men who have sex with men
(MSM), including male sex workers (MSWs), and among female sex
workers (FSWs), and injecting drug users (IDUs) (Abu-Raddad et al.,
2010a,b). Most surveys revealed low or absent HIV infection despite
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Fig. 1. The link between HIV and HSV-2 epidemiologies. The relationship between the
endemic saturated levels of HIV prevalence and HSV-2 prevalence in a prototype high-
risk population of men who have sex with men in the Middle East and North Africa.
Both infections are spreading in the same sexual network, but reach different
prevalence levels due to the biological differences between the two infections.
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Though these results might reinforce a perception that this region is
immune to HIV due to its socio-cultural fabric (Gray, 2004; Khawaja
et al., 1997; Lenton, 1997), these populations may be at risk for
potentially extensive HIV epidemics. Current low HIV prevalence may
be due to initial isolation of hard to reach populations in MENA from
high-risk networks in other parts of the world. Indeed, several recent
studies show rapidly escalating HIV epidemics among IDUs and MSM
in MENA (Abu-Raddad et al., 2010a,b). Alternatively, different sexual
networking patterns anduniversal circumcision statusmaybe limiting
the sexual spread of HIV.
Even when accurate risk behavior measures exist, they may
not establish a precise assessment of the true risk of HIV exposure.
Questionnaires, interviews, and focus groups provide only indirect
information regarding sexual activity (Obasi et al., 1999). The
sensitive nature of sexual behavior, informational limitations of ego-
centric data, and non-random social desirability and recall biases, can
introduce invalidity or inaccuracy of estimates for associations
or effects (Caldwell, 1989; Lee and Renzetti, 1990; Morris, 1993;
Wadsworth et al., 1993). Women may underreport sexual activity
while men may over-report (Catania et al., 1990). Validity of reported
risk behaviors that are illegal is likewise difﬁcult to ascertain (Pisani
et al., 2003).
It is also challenging to precisely quantify the multitude of facets
that deﬁne sexual behavior including rate of partnership formation,
contact with sex workers, heterogeneity in partner change rates, and
risk group and age cohort mixing (Abu-Raddad et al., 2006). Network
structure and concurrency of partnerships play a major role in HIV
transmission (Farjadian et al., 2003; Kretzschmar and Morris, 1996;
Morris, 1997; Watts and May, 1992): a monogamous member of a
stable sexual partnership can be at high risk of infection because of
connection through a primary partner, or a partner of a primary part-
ner, to a high-risk sexual network. Conversely, a person with frequent
partnership change remains at low risk if his/her network is closed
with low risk of HIV penetration.
Faced with these barriers, population data for other sexually
transmitted infections (STIs) take on importance as objective mea-
sures of HIV risk. Herpes simplex virus type-2 (HSV-2) is particularly
relevant to the dynamics of HIV transmission (Corey et al., 2004).
Genital herpes caused by HSV-2 is one of the most widespread
sexually transmitted infections (O'Farrell, 1999; Smith and Robinson,
2002; Weiss, 2004), and is currently the leading cause of genital ulcer
disease (GUD) in developed and developing countries (Ahmed et al.,
2003; Mertz et al., 1998; Morse, 1999). An estimated 536 million
people were living with this infection and 23.6 million new infections
occurred in 2003 (Looker et al., 2008). HSV-2 is transmitted almost
exclusively by sexual contact and results in production of lifelong
antibodies (van de Laar et al., 2001). There is repeatedly a very strong
observed correlation between HSV-2 infection and sexual risk
behavior as well as HSV-2 infection and HIV infection (Abu-Raddad
et al., 2008; Cowan et al., 1994; Cunningham et al., 1993; Obasi et al.,
1999; van de Laar et al., 2001). Measurement of HSV-2 antibodies in
the blood is therefore a convenient method to assess hidden levels of
sexual risk behavior (Nahmias et al., 1990).
There is also extensive observational evidence that HSV-2 in-
fection substantially increases HIV acquisition and transmission risk
due to enhanced genital inﬂammation in HSV-2 infected persons
(Freeman et al., 2006). At the population level, HSV-2, may have
played an important role in fueling the HIV epidemic in sub-Saharan
Africa (Abu-Raddad et al., 2008; Corey et al., 2004). The majority of
HIV infected persons are infected with HSV-2, and at an individual
level, HSV-2 is usually acquired before HIV (Corey et al., 2004). As
such, HSV-2 spreads along the paths of sexual risk and delineates
potential avenues of future sexual HIV spread in the population. In a
sense, HSV-2 infection may act as a “tour guide” for future HIV
infection, even when conventional behavioral measures such aspartnership change rates fail to predict the risk posed by the structure
of sexual networks (Nagelkerke et al., 2006). In a study of four cities in
Africa, only circumcision and HSV-2 prevalence were determinants of
large differences in HIV-1 prevalence (Buve et al., 2001). Because
circumcision is widespread in MENA, HSV-2 may take on primary
importance as a risk factor for HIV-1 infection in the region.
In this article,weuse amathematicalmodel that estimates thespread
ofHIVandHSV-2 to illustratehowtheextentof futureHIVepidemics can
be inferred by measuring endemic prevalence of HSV-2 within different
subpopulations.We also reviewHSV-2 prevalence data fromMENA, and
conclude that strategically implemented HSV-2 serosurveys are critical
in mapping HIV-1 risk among different populations within MENA.
Methods
Mathematical modeling
We used a compartmental modeling formalism to simulate the
potential course of HIV and HSV-2 epidemics in a high-risk population
in MENA (Online Supporting Appendix). The model is based on
extensions of earlier HIV and HSV-2 transmission models (Abu-
Raddad and Longini, 2008; Abu-Raddad et al., 2006; Garnett and
Anderson, 1993), but is applied, with no loss of generality, to a
prototype MSM population, that is a group of MSM individuals at
heterogeneous levels of risk behavior and where there is mixing
between the different risk groups through proportional as well as
assortative components (Online Supporting Appendix).
The formalism was built accommodating both deterministic and
stochastic solutions to allow for wider applicability of the modeling
framework. The deterministic version of the framework consists of a
system of four differential equations for each risk group of tenMSM risk
groups in the population. The stochastic version of the framework
assumes the same transition rates (hazard rates) as in the deterministic
version,butuses these transition rates to generate thestochastic process.
The deterministic framework can be usedwhenever the population size
in each risk group is large enough so that stochastic effects are not
inﬂuential. The stochastic framework can be used at any arbitrary
population size, but the computing time increases exponentially with
the population size leading to impracticality at large population sizes. In
this article we focused on the predictions for anMSM population where
someof the riskgroupswithin theMSMcommunity canbe small enough
to necessitate the use of the stochastic framework. Accordingly, all
reported results apart from Fig. 1 were generated using the stochastic
version of the model. Nevertheless, our modeling framework is general
enough to be used for large populations using the deterministic version.
We have also used the deterministic version to provide checks on the
results generated using the stochastic framework.
We chose model parameters for an MSM population since MSM is
a leading group at risk of HIV sexual transmission in MENA (Abu-
Raddad et al., 2010a,b); but the model and its key inferences apply
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inant mode of transmission. The model's biological input, including
HIV and HSV-2 natural history and transmission probabilities, is
described in the Online Supporting Appendix and in more detailed
form elsewhere (Abu-Raddad and Longini, 2008). Parameter values of
the HSV-2 sub-model are chosen according to the best available
evidence of HSV-2 biology including detailed data about the pattern of
HSV-2 reactivation in its clinical and subclinical forms (Abu-Raddad
et al., 2008; Mark et al., 2008) (supplementary information appendix
for Ref (Abu-Raddad et al., 2008)). Behavioral parameters in the
model are informed by data from the MENA HIV/AIDS Epidemiology
Synthesis Project as will be described later (Abu-Raddad et al., 2010a,
b), and are chosen to provide a representative heterogeneous risk
behavior structure typical of that of MSM as well as other risk groups
(Garnett and Anderson, 1993). We altered risk behavior in different
simulations to account for discrepant values of HSV-2 prevalence in
different populations and then observed the dynamics of HIV-1
spread. To disentangle sexual risk behavior from biological interac-
tions of HIV and HSV-2, we assumed no enhanced acquisition or
transmission probability of one infection due to the biology of the
other infection. Therefore, the only assumed link between HIV and
HSV-2 in this model is the common mode of transmission.
HSV-2 in MENA systematic review
We conducted a systematic review of HSV-2 epidemiology in
MENA by undertaking a literature search of Medline (PubMed) using
both free text and MeSH headings: (Herpesvirus 2, Human OR Herpes
Genitalis) AND (Middle East OR Islam OR Arabs OR Arab World OR
Africa, Northern OR Mauritania OR Sudan OR Somalia OR Djibouti OR
Pakistan). No language or year limitation was imposed. The inclusion
criterion was any publication with a serological measurement of
HSV-2 prevalence in any population group. We identiﬁed 30 publica-
tions for inclusion as of August 17, 2010. The countries included in our
systematic review are Afghanistan, Algeria, Bahrain, Djibouti, Egypt,
Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan,
Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, United
Arab Emirates, and Yemen (Fig. S1 of the Online Supporting Appendix
shows a map of the region).
We supplemented ourHSV-2Medline systematic reviewby the data
identiﬁed through the MENA HIV/AIDS Epidemiology Synthesis Project
(Abu-Raddad et al., 2010a,b). The Synthesis Project mandate was to
systematically collect, review, and synthesize all available data inMENA
on HIV, STIs, and sexual behavior, and was conducted through a
partnership with the World Bank, the MENA Regional Support Team
(RST) of Joint United Nations Programme on HIV/AIDS (UNAIDS), and
the EasternMediterranean Regional Ofﬁce (EMRO) of theWorld Health
Organization (WHO) (Abu-Raddad et al., 2010a). Detailed description of
the Synthesis Project systematic review can be found in (Abu-Raddad
et al., 2010a,b). The identiﬁed studies and data sources include, in
addition to nearly 4000 scientiﬁc sources of literature, hundreds of
country-level reports, governmental studies and publications, non-
governmental organizations' studies and publications, international
organizations' reports and databases, and other institutional reports
related to HIV and STIs in MENA (Abu-Raddad et al., 2010a,b). We also
searched theWHO/EMRO databases of notiﬁed HIV/AIDS cases and STIs
(WHO/EMRO), and consulted with public health ofﬁcials, and key
experts in the region and beyond.
Results
HSV-2 prevalence as a predictor of the distribution, evolution, and size of
future HIV epidemics
To illustrate the link between HIV and HSV-2 epidemiologies, we
calculated the relationship between HSV-2 prevalence and thepotential size of an HIV epidemic within an MSM sexual risk contact
structure of different risk groups mixing with each other. We varied
HSV-2 infection prevalence by altering the average level of sexual risk
behavior practiced in the sexual risk contact structure. We achieved
different levels of risk by varying the rate of partner change in the
whole population by the same multiplicative factor. Both viral
infections spread within the same contact structure, but at different
rates reﬂecting biological differences between the two infections.
Ourmodel demonstrates that HSV-2 prevalence is predictive of the
size of future endemic HIV prevalence, but the relationship is non-
linear (Fig. 1). A sexual risk contact structure where a low level of risk
behavior supports an HSV-2 prevalence of about 10%, cannot sustain
much endemic HIV transmission. Though HIV can be introduced into
such a sexual risk contact structure, HIV prevalence is not likely to
exceed 1%. In order for an HIV epidemic to reach greater than 5% in a
population (a concentrated HIV epidemic, Pisani et al., 2003), the level
of sexual risk behavior in the population must support an HSV-2
prevalence of about 20%. In settings where the level of risk behavior
supports an HSV-2 prevalence exceeding 60%, HIV prevalence is
predicted to exceed 35%. At very high levels of HSV-2 prevalence, HIV
prevalence values approach those of HSV-2. This non-linear relation-
ship between the two total-population prevalence levels for each
infection is also qualitatively seen for each risk group in the
population (Fig. S2). It must be noted here that these quantitative
results provide rough estimates to demonstrate this concept of the
link between the epidemiologies of the two infections rather than
strictly literal quantitative predictions.
Case scenarios illustrating HSV-2 prevalence as a biomarker of risk
behavior and potential HIV expansion
Fig. 2A shows the time course of an HIV epidemic in a prototype
MSM population whose endemic HSV-2 prevalence is 45%. HIV
infection is introduced into this population in the year 2000: it takes
several years before HIV infection sustains a considerable transmis-
sion. The epidemic peaks at approximately 20% prevalence following
two decades of expansion. In the simulation in Fig. 2B, HSV-2
prevalence is 10%. When HIV is introduced into this population, the
level of sexual risk behavior does not sustain infectious spread. Fig. 2C
shows the average of 100 simulations of HIV and HSV-2 epidemics
assuming that the two infections are introduced concurrently into an
MSM population. The HSV-2 infectious spread in its epidemic phase
grows more slowly than that of HIV, but eventually achieves a larger
endemic prevalence than that of HIV.
HSV-2 prevalence in MENA
We identiﬁed 14 references including HSV-2 prevalence measures
out of the 30 references identiﬁed through the Medline search. We
also identiﬁed another 14 relevant references through the wide
umbrella of the Synthesis Project search. Through this extensive
review, we found that HSV-2 research remains limited in MENA. The
majority of data were from the peer-reviewed literature, but some of
which were not indexed in Medline. Table 1 lists HSV-2 prevalence
measurements in MENA and related cultural settings. There is a
pattern of low prevalence among the general population, but
substantial prevalence among groups with identiﬁable risk factors
such as FSWs, MSM, “bar girls”, and STD clinic attendees. HSV-2
prevalence is lower overall than in all other regions of the world
(Table 2).
Several studies found higher HSV-2 prevalence levels (27%–54%)
among the general population, but there is reason to doubt the
accuracy of these studies. Diagnostic tests used in these publications
often suffered from high levels of cross-reactivity with herpes simplex
virus type 1 (HSV-1) antibodies (Ashley et al., 1991). In other studies,
we were unable to clarify, despite repeated attempts to contact the
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Fig. 2. A case scenario for HIV epidemic expansion in a prototype high-risk population
of men who have sex with men in the Middle East and North Africa. HIV infection is
introduced in year 2000 by one infected person with latent infection. A) HSV-2
prevalence is at about 45% prevalence reﬂecting high levels of sexual risk practices in
this population. B) HSV-2 prevalence is at about 10% prevalence reﬂecting relatively
low levels of sexual risk practices in this population. C) The two infections are
introduced concurrently in year 2000 by one infected person with latent infection of
both diseases. The HIV and HSV-2 prevalence curves shown reﬂect the average over 100
simulations for each epidemic.
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prevalence of HSV-2 in these reports is in doubt.
In certain countries, HSV-2 seroprevalence among certain age
groups achieves reasonably considerable levels. Fig. 3 shows age
stratiﬁed prevalence in a study from Morocco (Cowan et al., 2003).
Prevalence grows slowly formales and females in comparison to other
regions (see multiple data in Cowan et al., 2003 and Smith and
Robinson, 2002) suggesting that it takes a long time after sexual debut
for the risk of exposure to this STI to become appreciable.
Discussion
HSV-2 versus other biomarkers of risk
HSV-2 serology is a powerful marker of sexual risk that bypasses
shortcomings of risk behavior measures gathered through surveys,
and can be used in a similar manner to the use of hepatitis C infection
as a proxy for HIV risk of acquisition among IDUs (Vickerman et al.,
2010). HSV-2 is also a more powerful marker of sexual risk behavior
than other STIs in relation to HIV epidemic potential. Bacterial STIs
tend to cluster among populations at highly elevated risk behavior and
are therefore not as representative as HSV-2 to HIV infectious spread
which can affect a larger segment of the population (Abu-Raddad et al.,
2008; Boily and Masse, 1997; Brunham and Plummer, 1990; Yorkeet al., 1978). On the other hand, other viral STIs such as human pap-
illoma virus (HPV), aremuchmore infectious thanHIV andHSV-2, and
can affect a much larger part of the population than HIV and HSV-2
(Abu-Raddad et al., 2010a, 2008; Trottier and Franco, 2006). HSV-2
epidemiology is themost relevant of all STIs to HIV epidemiology. This
fact is manifested in the consistently strong association between these
two infections in multiple studies in diverse settings and populations
(Corey et al., 2004; Freeman et al., 2006). Other infections such as
hepatitis B and hepatitis C have modes of transmission other than
sexual intercourse and their epidemiologies reﬂect multiple risk
factors beyond sexual behavior.
Prevalence of HSV-2 in MENA and prediction of HIV epidemic potential
Using a mathematical model, we described how forthcoming HSV-
2 prevalence data could help identify the potential size of HIV
epidemics in MENA. Our literature review documents low levels of
HSV-2 infection in the general population suggesting that although
sexual risk practices are present, they may be at low levels compared
to other regions (Table 2). Low levels of cervical cancer (Abu-Raddad
et al., 2010a; Drain et al., 2002), which suggest low circulating levels
of oncogenic human papilloma virus, as well as the very low HIV
prevalence among the general population (Abu-Raddad et al., 2010a),
attest to this conclusion. Yet, HSV-2 prevalence appears to be con-
siderably higher among core groups for sexually transmitted infec-
tions, indicating a higher level of risk behavior.
MENApopulations, for cultural reasons, are unlikely to self-identify
as high risk for STIs or HIV infection. Tables 1, 3, and 4 illustrate how
HSV-2 prevalence can identify populations with elevated sexual risk
behavior such as MSM, FSWs, “bar girls”, and STD clinic attendees. In
order to prioritize the limited HIV prevention resources in this region,
it is critical to ﬁnely map elevated risk behaviors. In Pakistan,
surveillance work among different types of MSWs shows widely
variable HSV-2 prevalence, but very limited HIV prevalence (Table 5)
(Hawkes et al., 2009). The khusra MSWs (often known as hijra) have
much higher HSV-2 prevalence than the bantha or khotki MSWs, and
must be prioritized for HIV prevention interventions. Though HIV
prevalence continues to be low among hijra MSWs in Pakistan
(Hawkes et al., 2009; Pakistan National AIDS Control Program, 2005;
Pakistan National AIDS Control Program, 2006–07; Pakistan National
AIDS Control Program, 2008), it is probably only a matter of few years
before a substantial upsurge in HIV incidence occurs in this population
leading to a prevalence that possibly could reach 20% (Fig. 2A). Recent
rapid rise in HIV prevalence among hijras in Pakistan afﬁrms this
conjecture (HIV prevalence increased from 0.8% in 2005 to 1.8% in
2006, and to 6.4% in 2008, Pakistan National AIDS Control Program,
2005; Pakistan National AIDS Control Program, 2006–07; Pakistan
National AIDS Control Program, 2008). Meanwhile, HIV prevalence is
more likely to stay at low levels among bantha and FSWswhere HSV-2
prevalence is below10% (Fig. 2B). Any group inMENAwith highHSV-2
seroprevalence should be prioritized for HIV prevention interventions.
Despite overall low levels of HSV-2 prevalence, there is a
considerable heterogeneity, with some sub-regions showing higher
prevalence (such as Sudan and Morocco). Age stratiﬁed analyses of a
Moroccan cohort reveal a typical increase in prevalence with age,
though infection appears to be less commonly acquired during
adolescence than in other regions of the world (Cowan et al., 2003;
Smith and Robinson, 2002). Increasing prevalence in successive age
cohorts reﬂects cumulative acquisition of HSV-2 through adulthood.
Men in particular could be engaging in repeated episodes of high-risk
practices throughout their sexual activity lifespan, such as contacts
with FSWs. An alternative explanation might be a changing likelihood
of successive birth cohorts to be exposed to HSV-2 infection during
different eras (Burchell et al., 2006), or a low force of infection that
increases average age at infection (Anderson and May, 1991). The
former explanation seems unlikely as recent trends suggest increasing
Table 1
HSV-2 prevalence in different Middle East and North Africa populations as well as culturally related populations.
Country HSV-2 prevalence Assay Accuracy and
reproducibility
of measurementa
Bangladesh 12% (women attending primary care clinic) (Bogaerts et al., 2001) HSV-2 speciﬁc IgG ELISA (Gull Laboratories Inc.,
Salt Lake City, USA)
Good
Djibouti 2% (general population women), 5% (male blood donors), 49%
(luxury bar FSWs), 81% (street-based FSWs) (Marcelin et al., 2001)
Unknown Unknown
Egypt 32% (women, obstetric outpatient clinic) (el-Sayed Zaki and Goda, 2007) HSV-2 qualitative speciﬁc IgM ELISA (Equipar Via G,
Ferrari, Saronno, Italy)
Poor
Iran 28% (women, primary health care centers) (Kasraeian et al.) HSV-2 speciﬁc IgG ELISA (unknown; commercial test) Unknown
8.25% (pregnant women) (Ziyaeyan et al., 2007) Serum neutralization test Poor
23.3% (university students) (Tayyebi et al., 2010) HSV-2 speciﬁc IgG ELISA (Dia-pro, Italy) Good
Israel 9% (Arab and Jewish non-Soviet immigrants: pregnant women)
(Dan et al., 2003)
HSV-2 speciﬁc IgG ELISA (Savyon Diagnostics Ltd.,
Ashdod, Israel) (Ohana et al., 2000)
Good
2.4% (Arab STD clinic attendees) (Feldman et al., 2003) HSV-2 speciﬁc IgG ELISA (EIA-gG; Gull, USA)
(Ashley et al., 1998)
Good
Jordan 53% (male university students), 42% (female university students)
(Abuharfeil and Meqdam, 2000)
HSV-2 IgG ELISA (Ismunit, Italian Institute of
Immunology, Rome, Italy)
Fair
Lebanon 0.027% (general population women) (Karam et al., 2007) Unknown Unknown
Morocco 16.2% (ANC attendees), 13% (general population women), 10%
(general population men), 6.7% (STD clinic attendees) (WHO/EMRO)
Unknown Unknown
26% (urban women with a median age of 40 years) (Patnaik et al., 2007) Western blot (reference gold standard) (Ashley, 1998;
Ashley et al., 1988; Ashley and Wald, 1999)
Excellent
12.9% (ANC attendees), 9.2% (male HIV sentinel surveillance), 6.5%
(military personnel) (Cowan et al., 2003)
HSV-2-speciﬁc IgG ELISA (HerpesSelect; Focus
Technologies, CA, USA)
Good
Pakistan 3.4% (urban men) (Mir et al., 2009) HSV-2 speciﬁc IgG ELISA (unknown; commercial test) Unknown
11.0% (IDUs), 6.0% (IDUs) (Platt et al., 2009) HSV-2-speciﬁc IgG ELISA (HerpesSelect; Focus
Technologies, Cypress, CA, USA)
Good
8% (FSWs), 4.7% (FSWs), 7.4% (MSWs; bantha), 2.5% (MSWs; bantha),
14% (MSWs; khotki), 25% (MSWs; khotki), 54% (MSWs; khusra),
31.3% (MSWs; khusra) (Hawkes et al., 2009)
HSV-2-speciﬁc IgG ELISA (HerpesSelect; Focus
Technologies, Cypress, CA, USA)
Good
Saudi Arabia 27% (pregnant women) (Ghazi et al., 2002) HSV-2-speciﬁc IgG ELISA (Wampole Laboratories,
New Jersey, USA)
Poor.
Sudan 27% (women Sudanese refugees in Ethiopia), 26% (men Sudanese
refugees in Ethiopia) (Holt et al., 2003)
Glycoprotein G-based immunoblot assays
(Centers for Disease Control and Prevention
laboratory, Atlanta, USA) (Schmid et al., 1999)
Fair
5.5% (household cluster survey; South Sudan), 4.5% (household cluster
survey; South Sudan), 6.1% (household cluster survey; South Sudan)
(Kaiser et al., 2006)
Glycoprotein G-based immunoblot assays
(Centers for Disease Control and Prevention
laboratory, Atlanta, USA).
Fair
Syria 0% (pregnant women), 0% (general population women), 0.3%
(general population men), 0% (neonates), 9.5% (STD clinic attendees),
8.0% (women with cervical cancer), 20% (“bar girls”), 34% FSWs
(Ibrahim et al., 2000)
HSV-2-speciﬁc IgG ELISA (Radim company,
Sulzbach, Germany)
Good
Turkey 89% (women with pregnancy complication) (Cengiz et al., 1993b) HSV-2 IgG ELISA (Unknown) Unknown
63.1% (pregnant women) (Duran, 2004; Duran et al., 2004) IgG antibodies Poor
5.0% (pregnant women) HSV-2-speciﬁc IgG ELISA (Euroimmun, Germany)
(Aksözek et al., 2004; Eing et al., 2002)
Good
5.5% (blood donors), 4.8% (sexually active adults), 8.3% (hotel staff),
17.3% (patients with genital warts), 60% (FSWs) (Dolar et al., 2006)
26% (MSM) (Cengiz et al., 1992; Cengiz et al., 1993a) HSV-2-speciﬁc IgG ELISA (Unknown) Unknown
53.5% (rural general population women) (Maral et al., 2009) EIAgen Herpes Simplex 2 IgG Code 08.1007.2
(ADALTIS ItaliaS.p.A. Via Magnanelli, 2-40033
Casalecchio di Reno)
Unknown.
80% (FSWs) (Gul et al., 2008) HSV-2-speciﬁc IgG ELISA (Euroimmun, Germany)
(Aksözek et al., 2004; Eing et al., 2002)
Good
United Arab Emirates 17.7% (blood donors including migrant workers), 7.3%
(migrant workers), 9.7% (migrant workers) [N.J. Nagelkerke,
personal communication]
HSV-2-speciﬁc IgG ELISA (Kalon Biological, Ltd.,
Surrey, United Kingdom)
Good, but relatively
insensitive to new
diagnosis.
FSW= female sex worker, MSW=male sex workers, MSM=menwho have sexwithmen, ANC= ante-natal clinic, STD= sexually transmitted diseases, IDU= injecting drug user,
bantha = biological males with a male gender identity, khotki=biological males who dress as men but have “female soul” and feminized traits, khusra= transgenders who dress as
women (also known as hijra).
a Criteria used to judge the conﬁdence in the serology measurements were the robustness of the serology test used, procedures used to conduct the serology test, and amount of
available information on the serology test. We labeled any test with greater than 95% speciﬁcity and sensitivity excellent; tests with greater than 90% sensitivity and speciﬁcity good;
tests with greater than 75% sensitivity and speciﬁcity fair; all other tests were considered poor. Poor tests tend to suffer from cross-reactivity with other infections, particularly HSV-1.
We also judged a test to be poor if authors used or described tests that have not been validated in the medical literature. In several cases, we were not able to identify the test used
from manuscripts and numerous attempts to contact authors: these were labeled unknown.
177L.J. Abu-Raddad et al. / Epidemics 2 (2010) 173–182sexual risk behavior in the young population (Abu-Raddad et al.,
2010a).
HSV-2 research and trends in sexual risk behavior in MENA
The use of age cohorts will be critical to study the nature of HSV-2
prevalence in MENA. Rates of HSV-2 prevalence often change mostrapidly among adolescents and young adults, suggesting that HSV-2
can be used to gauge recent changes in risk behavior among young age
cohorts (Obasi et al., 1999; Slomka, 1996; van de Laar et al., 2001; Xu
et al., 2006). MENA is characterized by a massive youth bulge. One-
ﬁfth of the population, 95 million people, are in the 15–24 years age
group (Assaad et al., 2007; Roudi-Fahimi and Ashford, 2008; UNAIDS
RST MENA, 2007) which is normally the age of initiation of sexual
Table 3
HSV-2 prevalence in different population groups in a study from Syria (Ibrahim et al.,
2000).
Population Population size Prevalence HSV-2 (%)
Healthy men 305 0.3
Healthy women 349 0.0
Pregnant women 55 0.0
Neonates 101 0.0
Sexually transmitted disease patients 21 9.5
Cervical cancer patients 51 8.0
Bar girls 125 20.0
Female sex workers 101 34.0
Table 2
HSV-2 prevalence in the general population in different regions of the world (O'Farrell,
1999; Paz-Bailey et al., 2007; Pebody et al., 2004; Smith and Robinson, 2002; Weiss,
2004).
Region HSV-2 prevalence
Asia 10% to 30%
Europe 4% to 24%
Latin America 20% to 40%
Middle East and North Africa 0% to 15%
North America 18% to 26%
Sub-Saharan Africa 10% to 80%
178 L.J. Abu-Raddad et al. / Epidemics 2 (2010) 173–182activities (Roudi-Fahimi and Ashford, 2008). This youth cohort
represents the largest potentially-vulnerable population to HIV in
MENA (Assaad et al., 2007). Youth are experiencing high rates of
unemployment, delayed marital age, increased premarital sex, con-
ﬂict morbidity, increased mobility, peer pressure to engage in risk
behavior, and changing lifestyle norms (Busulwa, 2003; UNAIDS RST
MENA, 2007, 2008). Population-based data of HSV-2 among youth
collected sequentially in time would be valuable to determine trends
of sexual risk behavior.
Epidemic growth and endemicity of HSV-2 and HIV infections
Though overall HSV-2 transmission probability per coital act
during shedding is larger than that of HIV (Abu-Raddad et al., 2008;
Wald et al., 2006, 2001), HSV-2 transmission occurs only during HSV-
2 primary infection and reactivations, thereby slowing growth of HSV-
2 epidemics. HIV transmission probability is considerable throughout
the natural history of infection (Wawer et al., 2005) allowing for more
rapid epidemic expansion. However, the infectious period for HIV is
limited by disease mortality after about ten years, whereas the
infectious period of HSV-2 persists for the duration of sexual activity
of the infected host. Therefore, HIV cannot sustain as high a
prevalence as that of HSV-2 in the population. HSV-2 prevalence
reaches high levels but may need as much as several decades to reach
its peak. Once HSV-2 reaches its endemic saturation, the HSV-2 force
of infection becomes substantially larger than that of HIV and it is
muchmore likely for a susceptible person entering the sexually active
population to be infected with HSV-2 prior to HIV.
There are no longitudinal data of HSV-2 prevalence in MENA and it
is not known whether HSV-2 prevalence has saturated its epidemic
potential among the different populations in the region. Based on data
from other regions (Korenromp et al., 2002a,b,c; O'Farrell, 1999;
Smith and Robinson, 2002; Weiss, 2004), HSV-2 prevalence may have
reached endemic levels within MSM in MENA. In most of Africa for
example, the HSV-2 epidemic started no later than the ﬁrst half of the
twentieth century (Nahmias et al., 1990), and reached its peak prior to0
5
10
15
20
25
0 5 10 15 20 25 30 35 40 45 50
Age
Pr
ev
al
en
ce
 (%
)
HSV-2 prevelance (%) among adult females
HSV-2 prevelance (%) among adult males
Fig. 3.HSV-2 prevalence for selected populations by age group inMorocco (Cowan et al.,
2003).the HIV epidemic (Abu-Raddad et al., 2008). However some high-risk
populations in MENA have HSV-2 prevalence measures (Table 1) that
are considerably lower than those in corresponding populations in
other regions (Corey et al., 2004; O'Farrell, 1999; Smith and Robinson,
2002; Weiss, 2004). One cannot exclude that HSV-2 could be in the
midst of early epidemic expansion in some high-risk populations in
MENA.
If HSV-2 has only recently been introduced into a high-risk
population in MENA, its use as a proxy to map levels of existing risk
behaviors may be limited. Indeed, if risk behavior is increasing within
certain subpopulations in MENA, then this may allow for conditions
that promote both HSV-2 and HIV expansion. Because our model
suggests that HSV-2 prevalence is best predictive of HIV spread when
an endemic HSV-2 level is established, serial measures of HSV-2
prevalence will be necessary to rule out an enlarging HSV-2 epidemic.
A related conclusion of our simulations among MSM is that a cross-
sectional study that reveals an HIV-1 prevalence greater than or
equivalent to that of HSV-2 suggests that both HSV-2 and HIV
prevalence may be in an expansion phase.
Potential study limitations and limitations of available HSV-2 evidence
in MENA
Our study has several limitations. First, our model's quantitative
predictions are generated for a speciﬁc sexual risk contact structure
and cannot be generalized for all populations. Sexual networks vary in
structure (Ghani and Garnett, 2000; Morris, 1997) and this variation
may affect HIV and HSV-2 infectious spread differently. It is not our
aim to explore the complexity of links between HIV and HSV-2
epidemiologies. For this reason, we also did not include biological
interactions between HSV-2 and HIV in our model. Rather, we
explored generic conclusions regarding the predictive nature of HSV-
2 prevalence as a measure of risk for HIV epidemic propagation. These
ﬁndings do not apply for an HIV epidemic fueled by non-sexualmodes
of transmission such as injecting drug use.We also did not incorporate
the overlap of risk behaviors such as part of the MSM population
engaging in sexual risk behavior and injecting drug use at the same
time. Existing evidence in MENA suggests a considerable overlap of
risk factors between different risk groups (Abu-Raddad et al., 2010a,
b). For example, often as much as 15% of MSM inject drugs and 30%
report anal sex with injecting drug users (Mumtaz et al., 2010).Table 4
HSV-2 prevalence in different population groups in a study from Turkey (Dolar et al.,
2006).
Population Population size Prevalence of HSV-2 (%)
Sexually active adults 725 4.8
Pregnant women 300 5.0
Blood donors 200 5.5
Patients with genital warts 110 17.3
Hotel staff 264 8.3
Female sex workers 483 60.0
Table 5
Prevalence of HSV-2 and HIV in different high-risk populations in a study from Pakistan
(Hawkes et al., 2009).
Type of
population
Rawalpindi Abbottabad
HSV-2
prevalence
(%)
HIV
prevalence
(%)
HSV-2
prevalence
(%)
HIV
prevalence
(%)
Bantha MSWs 7.4 0.5 2.5 0
Khotki MSWs 14 0 25 0
Khusra MSWs 54 2.4 31.3 0
FSWs 8.0 0 4.7 0
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necessarily of current risk behaviors, and therefore HSV-2 prevalence
may reﬂect current or recent risk behavior only among youth (Obasi
et al., 1999; Slomka, 1996; van de Laar et al., 2001; Xu et al., 2006).
However, this limitation should not affect the utility of using HSV-2
prevalence as a powerful marker of risk behavior and HIV epidemic
potential in MENA. The populations for which this methodology is
suggested are either young in age (high-risk populations), or
populations with variable age structure (general population) but
whose HSV-2 prevalence appears, given the aforementioned data, to
be at low levels. A low HSV-2 prevalence in a population suggests
that this population, irrespective of its age structure, may not have
practiced high levels of sexual risk behaviors in the past.
Multiple studies on MSM in MENA in different countries have
shown that themajority of sexually active MSM are young in their 20s
and that these young MSM changed their sexual partners most often
(Abu-Raddad et al., 2010a; El-Rahman, 2004; El-Sayyed et al., 2008;
Elrashied, 2006; Mishwar, 2008). In Pakistan, MSWs had an average
age of 22.3 (Pakistan National AIDS Control Program, 2005), 21.3
(Pakistan National AIDS Control Program, 2006–07), and 21.7
(Pakistan National AIDS Control Program, 2008) years, and started
commercial sex at an average age of 16.9 (Pakistan National AIDS
Control Program, 2005), 15.9 (Pakistan National AIDS Control
Program, 2006–07), and 16.2 (Pakistan National AIDS Control
Program, 2008) years. Furthermore, the vast majority of FSWs in
MENAhave been identiﬁed inmultiple studies in different countries to
be well below age 30, and young FSWs most often had the highest
client volume (Abu-Raddad et al., 2010a; ACCORD, 2005, 2006; Ati,
2005; Syria National AIDS Programme, 2004; Yousif, 2006). Lastly,
multiple studies in different countries show also that the dominant
proﬁle of IDUs, who engage in multiple sexual risk behaviors (Abu-
Raddad et al., 2010a,b), is that of young men raised in large families
shattered by unemployment, economic hardship, and urban–rural
migration (Abu-Raddad et al., 2010a; Aﬁﬁ and El-Sousi, 2004; Bolhari
and Mirzamani, 2002; Michael et al., 2003; Mishwar, 2008; Pakistan
National AIDS Control Program, 2005; Pakistan National AIDS Control
Program, 2006–07; Shareef et al., 2006; Tiouiri et al., 1999; Zamani et
al., 2006).
We assumed no enhanced acquisition or transmission probability
of one infection due to the biology of the other infection in order to
disentangle sexual risk behavior from biological interactions of HIV
and HSV-2. In light of the fact that recent clinical trials have failed to
document effects of HSV-2 suppressive therapy on HIV incidence, the
degree of epidemiological synergy between HSV-2 and HIV-1
incidence remains uncertain (Celum et al., 2008; Lingappa et al.,
2010; Watson-Jones et al., 2008). If such biological synergy between
HIV and HSV-2 exists (Abu-Raddad et al., 2008), it can affect the
epidemic spread and heterogeneity of disease burden, but at the same
time, it would strengthen our argument for using HSV-2 as a predictor
of the HIV epidemic potential since HSV-2 prevalence would reﬂect
levels of risk behavior as well as the additional biological suscepti-
bility to HIV infection arising from the biology of HSV-2 infection. HIV
mortality may also affect, as a matter of principle, HSV-2 prevalencecomplicating the relationship between the epidemiologies of the two
infections. However earlier work has suggested that this effect is very
minor (Abu-Raddad et al., 2008).
Our focus in this article was on the qualitative ﬁndings linking the
epidemiologies of HIV and HSV-2 rather than on precise quantitative
estimates. Therefore we did not incorporate uncertainty analyses on
the parameters of the model. Incorporation of such analyses would
produce a range of estimates around the point estimates of our pre-
dictions presented here. Though we presented results for an MSM
population, our qualitative results are of general nature and apply to
heterosexual sex networks. Heterogeneities in the HIV transmission
process due to variability in risk behavior, transmission probability
and gender, can inﬂuence the distribution of the infection burden, but
maintain the predictive effect of HSV-2 as a proxy of the risk of HIV
acquisition for each subpopulation as can be seen in Fig. S2 of the
Online Supporting Appendix.
Many HSV-2 seroprevalence studies to date in MENA suffer from
methodological limitations due to use of inappropriate whole virus
based assays that do not distinguish antibodies to HSV-2 from those
against HSV-1. Due to the wide burden of HSV-1 infection in the
region (Cowan et al., 2003; Smith and Robinson, 2002), assays that
accurately differentiate chronic HSV-1 from HSV-2 infection are
imperative. HSV-1 infection that is usually acquired during childhood
through oral but not sexual contact, has a very high prevalence in
MENA (Cowan et al., 2003; Smith and Robinson, 2002), and shows
extensive sequence homologywith HSV-2 (Gentry et al., 1988). HSV-1
causes a high proportion of incident genital herpes in some
populations due to oro-genital as opposed to purely genital
transmission (Lafferty et al., 2000; Langenberg et al., 1999; Lowhagen
et al., 2000; Nilsen andMyrmel, 2000; Ribes et al., 2001; Roberts et al.,
2003; Scoular et al., 2002; Tran et al., 2004). This trend has been
observed regionally only in Israel (Samra et al., 2003), but could
become more widespread if there is a trend of increased oral sex.
Clinical exam is of no utility in differentiating HSV-1 and HSV-2
lesions, and up to 90% of HSV-2 seropositive persons do not recall
having genital herpes (Corey and Handsﬁeld, 2000; Cowan et al.,
1994; Fleming et al., 1997). For these reasons, monitoring of HSV-2
infection must include accurate serologic assays. Several available
serological assays have high speciﬁcity and sensitivity, though their
results still need to be validated by population with Western blot
assay (WBA) because of variable performance characteristics in
different regions (Ashley-Morrow et al., 2004; Ashley and Wald,
1999). For these reasons our classiﬁcation of serology tests as
excellent, good, fair or poor should be interpreted cautiously as
assay utility may vary regionally.
Finally, HSV-1 infection could hypothetically have a protective
effect against HSV-2 acquisition (Cowan et al., 1994; Mertz et al.,
1985), thereby partially contributing to lower regional prevalence of
HSV-2. However, evidence for a protective effect is conﬂicting (Brown
et al., 1997; Cowan et al., 2003; Langenberg et al., 1999), and in many
settings, high HSV-1 prevalence (Cowan et al., 2003; Smith and
Robinson, 2002) has not tainted the predictive power of HSV-2 as a
proxy for sexual risk behavior. In fact, overwhelming evidence afﬁrms
the utility of HSV-2 as a marker of risk behavior irrespective of HSV-1
prevalence (Cowan et al., 2003,1994; Cunningham et al., 1993; Dan
et al., 2003; Obasi et al., 1999; van de Laar et al., 2001). Near universal
male circumcision coverage in MENA is also not likely to explain low
HSV-2 prevalence as male circumcision reduces HSV-2 sero-incidence
by at most 30% (Bailey, 2007; Tobian et al., 2009; Weiss et al., 2006).
Summary of ﬁndings
In conclusion, we identify HSV-2 serology as a powerful marker of
sexual risk behavior that should be a standard component in any
proposed HIV surveillance efforts in MENA. This is particularly true for
studies incorporating integrated bio-behavioral surveillance surveys
180 L.J. Abu-Raddad et al. / Epidemics 2 (2010) 173–182among high-risk populations. At present, HSV-2 prevalence in the
general population in MENA is among the lowest globally (Table 2)
(O'Farrell, 1999; Paz-Bailey et al., 2007; Pebody et al., 2004; Smith and
Robinson, 2002; Weiss, 2004). This provides an indication that sexual
risk behavior in the general population in MENA is low, and that HIV
infection will have limited inroads into this population. Yet, HSV-2
prevalence levels in MENA populations with identiﬁable risk
behaviors are substantial and on occasion comparable to those in
other regions (Smith and Robinson, 2002). Our model suggests that in
a population where HSV-2 is already at a relatively high endemic
level, HIV prevalence may continue at low levels for many years.
However, there exists a potential for rapid exponential spread. Such
populations should be a priority for early public health interventions
including surveillance mechanisms for more intensive data collection
to track the potential for further spread.
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